glp 1 agonist oral GLP-1: A Needle-Free Solution for Weight Loss Innovent gets IND for oral

Amycretin is a next-generation unimolecular dual GLP-1/amylin receptor agonist that showed up to 24.3% weight loss in early trials, substantially exceeding semaglutide and potentially exceeding even CagriSema

Michos said the risk reduction observed with major CV events in the FLOW trial was just as important as the primary outcome due to the high CV risk for people with CKD, especially as their kidney disease progresses

10.1056/NEJM199901143400207 2

Clinical Kidney Journal, 15

Retatrutide is expected to be a once-weekly subcutaneous injection, similar to other GLP-1 medications

[DOI] [PubMed] [Google Scholar] 26.Escalada F.J